Serum MiRNA panel as potential biomarkers for chronic hepatitis B with persistently normal alanine aminotransferase

Clinica Chimica Acta

Volumn 451, Issue , 2015, Pages 232-239

  Tan, Youwen ^a   Ge, Guohong ^a   Pan, Tengli ^a   Wen, Danfeng ^a   Gan, Jianhe ^a  

^a The Third People's Hospital of Zhenjiang Affiliated Jiangsu University   (China)

Author keywords

Alanine aminotransferase; Biomarker; Chronic; Hepatitis B virus; microRNA; Non invasive

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; MICRORNA;

ADULT; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; FEMALE; GENETICS; HEPATITIS B, CHRONIC; HUMAN; MALE; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL MODEL;

ADULT; ALANINE TRANSAMINASE; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LOGISTIC MODELS; MALE; MICRORNAS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84952977417     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.10.002     Document Type: Article

References (48)

1. Poland G.A., Jacobson R.M. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N. Engl. J. Med. 2004, 351(27):2832-2838.
2. Ning L.H., Hao J., Liao Z.L., Zhou Y.Y., Guo H., Zhao X.Y. A survey on the current trends in the management of hepatitis B in China. Eur. J. Gastroenterol. Hepatol. 2012, 24(8):884-889.
3. Chu M.J., Phillips A.R., Hosking A.W., MacDonald J.R., Bartlett A.S., Hickey A.J. Hepatic mitochondrial function analysis using needle liver biopsy samples. PLoS One 2013, 8(10):e79097.
4. Claudi C., Henschel M., Vogel J., Schepke M., Biecker E. Fulminant sepsis after liver biopsy: a long forgotten complication?. World J. Clin. Cases 2013, 1(1):41-43.
5. Dhanda A.D., Collins P.L., McCune C.A. Is liver biopsy necessary in the management of alcoholic hepatitis?. World J. Gastroenterol. 2013, 19(44):7825-7829.
6. van Beek D., Funaki B. Hemorrhage as a complication of percutaneous liver biopsy. Semin. Interv. Radiol. 2013, 30(4):413-416.
7. Moon J., Kang W., Oh P.C., et al. Serum transaminase determined in the emergency room predicts outcomes in patients with acute ST-segment elevation myocardial infarction who undergo primary percutaneous coronary intervention. Int. J. Cardiol. 2014, 177(2):442-447.
8. Wang H., Xue L., Yan R., et al. Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS One 2013, 8(11):e80585.
9. Papatheodoridis G.V., Manolakopoulos S., Liaw Y.F., Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J. Hepatol. 2012, 57(1):196-202.
10. Lai M., Hyatt B.J., Nasser I., Curry M., Afdhal N.H. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J. Hepatol. 2007, 47(6):760-767.
11. Kumar M., Sarin S.K., Hissar S., et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008, 134(5):1376-1384.
12. Toffanin S., Sia D., Villanueva A. MicroRNAs: new ways to block tumor angiogenesis?. J. Hepatol. 2012, 57(3):490-491.
13. Chen Y.J., Zhu J.M., Wu H., et al. Circulating microRNAs as a fingerprint for liver cirrhosis. PLoS One 2013, 8(6):e66577.
14. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9(6):654-659.
15. Li Y., Kowdley K.V. MicroRNAs in common human diseases. Genomics Proteomics Bioinformatics 2012, 10(5):246-253.
16. Bala S., Petrasek J., Mundkur S., et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012, 56(5):1946-1957.
17. Waidmann O., Bihrer V., Pleli T., et al. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J. Viral Hepat. 2012, 19(2):e58-e65.
18. Waidmann O., Koberle V., Brunner F., Zeuzem S., Piiper A., Kronenberger B. Serum microRNA-122 predicts survival in patients with liver cirrhosis. PLoS One 2012, 7(9):e45652.
19. Wang J., Li J., Shen J., Wang C., Yang L., Zhang X. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer 2012, 12:227.
20. Lamba V., Ghodke-Puranik Y., Guan W., Lamba J.K. Identification of suitable reference genes for hepatic microRNA quantitation. BMC Res. Notes 2014, 7(1):129.
21. Blanco-Calvo M., Calvo L., Figueroa A., Haz-Conde M., Anton-Aparicio L., Valladares-Ayerbes M. Circulating microRNAs: molecular microsensors in gastrointestinal cancer. Sensors 2012, 12(7):9349-9362.
22. Ge Y., Chen G., Sun L., Liu F. MicroRNA-29 and fibrosis diseases. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2011, 36(9):908-912.
23. He Y., Huang C., Zhang S.P., Sun X., Long X.R., Li J. The potential of microRNAs in liver fibrosis. Cell. Signal. 2012, 24(12):2268-2272.
24. Cermelli S., Ruggieri A., Marrero J.A., Ioannou G.N., Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011, 6(8):e23937.
25. Chen Y.P., Jin X., Xiang Z., Chen S.H., Li Y.M. Circulating MicroRNAs as potential biomarkers for alcoholic steatohepatitis. Liver Int. 2013, 33(8):1257-1265.
26. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24(2):289-293.
27. Peltier H.J., Latham G.J. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008, 14(5):844-852.
28. Zhang H., Li Q.Y., Guo Z.Z., et al. Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B. World J. Gastroenterol. 2012, 18(37):5188-5196.
29. Li G., Cai G., Li D., Yin W. MicroRNAs and liver disease: viral hepatitis, liver fibrosis and hepatocellular carcinoma. Postgrad. Med. J. 2014, 90(1060):106-112.
30. Li Z.J., Ou-Yang P.H., Han X.P. Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells. Cell. Signal. 2014, 26(1):141-148.
31. Marin J.J., Bujanda L., Banales J.M. MicroRNAs and cholestatic liver diseases. Curr. Opin. Gastroenterol. 2014.
32. Papaconstantinou I., Karakatsanis A., Gazouli M., Polymeneas G., Voros D. The role of microRNAs in liver cancer. Eur. J. Gastroenterol. Hepatol. 2012, 24(3):223-228.
33. Steer C.J., Subramanian S. Circulating microRNAs as biomarkers: a new frontier in diagnostics. Liver Transpl. 2012, 18(3):265-269.
34. Smith-Vikos T., Slack F.J. MicroRNAs and their roles in aging. J. Cell Sci. 2012, 125(Pt 1):7-17.
35. Starkey Lewis P.J., Merz M., Couttet P., et al. Serum microRNA biomarkers for drug-induced liver injury. Clin. Pharmacol. Ther. 2012, 92(3):291-293.
36. Gougelet A., Colnot S. MicroRNA: new diagnostic and therapeutic tools in liver disease?. Med. Sci. 2013, 29(10):861-867.
37. Hsu S.H., Ghoshal K. MicroRNAs in liver health and disease. Curr. Pathobiol. Rep. 2013, 1(1):53-62.
38. Jopling C.L., Yi M., Lancaster A.M., Lemon S.M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309(5740):1577-1581.
39. Cheung O., Puri P., Eicken C., et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008, 48(6):1810-1820.
40. Tan Y., Ge G., Pan T., Wen D., Gan J. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One 2014, 9(8):e105192.
41. Xu J., Wu C., Che X., et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol. Carcinog. 2011, 50(2):136-142.
42. Abu El Makarem M.A., Abdel-Aleem A., Ali A., et al. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Ann. Hepatol. 2011, 10(3):296-305.
43. Tomimaru Y., Eguchi H., Nagano H., et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J. Hepatol. 2012, 56(1):167-175.
44. Bala S., Tilahun Y., Taha O., et al. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J. Transl. Med. 2012, 10:151.
45. Ji F., Yang B., Peng X., Ding H., You H., Tien P. Circulating microRNAs in hepatitis B virus-infected patients. J. Viral Hepat. 2011, 18(7):e242-e251.
46. Li L.M., Hu Z.B., Zhou Z.X., et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010, 70(23):9798-9807.
47. Zhou J., Yu L., Gao X., et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J. Clin. Oncol. 2011, 29(36):4781-4788.
48. Abdalla M.A., Haj-Ahmad Y. Promising candidate urinary MicroRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus egyptian patients. J. Cancer 2012, 3:19-31.